Howard Brown Health $1M Grant for HIV Prevention and Care Services
The funds will support Howard Brown’s integrated campaign to reduce new HIV infections in Chicago
(Chicago, IL, August 29, 2022) – Howard Brown Health has been awarded a three-year, $1 million grant from Gilead Sciences, Inc. to fund a campaign aimed at reducing new HIV infections in Chicago. The campaign will follow a three-prong approach focused on outreach, retention and education.
“We’re thankful to Gilead for supporting our work in HIV prevention and care with this generous grant,” said Katie Metos, Vice President of External Relations. “The project will provide resources for Howard Brown to increase the retention of patients in our care, launch a targeted HIV education campaign, and augment our integrated care team model with a focus on HIV.”
In 2019, 19% of all new HIV diagnoses in Chicago were diagnosed at Howard Brown Health. From January through June of 2022, the agency has diagnosed 73 people with HIV, on track to outpace 2021’s total diagnoses.
Howard Brown Health provides full-spectrum HIV services, from screening, biomedical prevention interventions, to case management support, to long-term care. More information is available at howardbrown.org
Erik Roldan, Director of Marketing and Communications, (cell) 312.206.2167, email@example.com
Rooted in LGBTQ+ liberation, Howard Brown Health provides affirming healthcare and mobilizes for social justice. We are agents of change for individual wellbeing and community empowerment.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, millions of people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.